MedTrace Logo

The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients

NCT06836128 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-07-09

No results posted yet for this study

Summary

The study aims to evaluate the effects of combination of metformin with NAC in PCOS on biochemical and hormonal parameters.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

N-acetyl cysteine

N-Acetyl Cysteine (NAC) has antioxidant properties and is essential for the body's production of glutathione, and both glutathione and NAC are potent antioxidants.

DRUG

Metfomin

metformin is commonly used for managing polycystic ovary syndrome (PCOS) due to its benefits in addressing several underlying features of the condition. While it is not officially approved by regulatory agencies like the FDA for PCOS, it is widely recognized and recommended in clinical practice guidelines as an off-label treatment for PCOS, particularly in women with insulin resistance and metabolic dysfunction.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Samar F Farid, PhD · Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University

  • Eglal A Mostafa Bassiouny, PhD · Lecturer of Clinical Pharmacy Faculty of Pharmacy, Cairo University

  • Amr Z Abdelhamid, PhD · Obstetrics and Gynaecology Lecturer Kasr Al-Ainy School of Medicine, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-02-01
Completion
2026-05-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06836128 on ClinicalTrials.gov